Trastuzumab Deruxtecan (T-Dxd) + Durvalumab (D) As First-Line (1L) Treatment For Unresectable Locally Advanced/Metastatic Hormone Receptor-Negative (Hr-), Her2-Low Breast Cancer: Updated Results From Begonia, A Phase 1B/2 Study
Durvalumab;Trastuzumab Deruxtecan
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Trastuzumab Deruxtecan (T-Dxd) + Durvalumab (D) As First-Line (1L) Treatment For Unresectable Locally Advanced/Metastatic Hormone Receptor-Negative (Hr-), Her2-Low Breast Cancer: Updated Results From Begonia, A Phase 1B/2 Study ### Output: Durvalumab;Trastuzumab Deruxtecan